Loading clinical trials...
Loading clinical trials...
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Conditions
Interventions
Itacitinib
Ruxolitinib
Locations
26
United States
Arizona Oncology Associates
Tempe, Arizona, United States
UC Irvine Medical Center
Orange, California, United States
Anschutz Cancer Pavilion - University Of Colorado
Aurora, Colorado, United States
Rocky Mountain Cancer Center
Colorado Springs, Colorado, United States
Rocky Mountain Cancer Center
Denver, Colorado, United States
Norwalk Hospital
Norwalk, Connecticut, United States
Start Date
January 26, 2018
Primary Completion Date
March 14, 2020
Completion Date
June 1, 2021
Last Updated
June 16, 2022
NCT03011372
NCT02953704
NCT03123588
Lead Sponsor
Incyte Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions